Semi-quantitative analysis of ¹⁸F fluorodeoxyglucose uptake in the assessment of disease activity and therapeutic response in rheumatoid arthritis: An institutional experience

Abstract

¹⁸F fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET) can be used to image synovial inflammation in patients with rheumatoid arthritis (RA). Recently, clinical application of novel therapies for RA, such as tumor necrosis factor-α (TNF-α) inhibitor and anti-interleukin-6 receptor antibody, has been introduced. The radiological assessment of disease activity changes of patients who underwent these therapies will help the clinicians to obtain more information about the patients and to decide drug withdrawal or change of medication. It is considered that ¹⁸F-FDG PET scan is generally very expensive; however, the information from ¹⁸F-FDG PET about patients during biological treatments helps discontinuation of these treatments with incomplete response despite its high costs and with possible side effects such as malignant lymphoma. In this study, we evaluated if the ¹⁸F-FDG uptake of the affected joints represented by standardized uptake value (SUV) correlated with the clinical assessment of patients with RA. In addition, we would like to evaluate if there was a correlation between the difference of SUV and improvement of clinical findings in RA patients undergoing anti TNF therapies. RA patients who underwent anti-TNFα therapies in a tertiary care hospital were assessed using whole-body ¹⁸F-FDG PET/computed tomography (CT). PET assessments were performed on hip joints, knees, shoulders, wrists, ankles, MCP, and PIP for a total of 28 joints in each patient. The ¹⁸F–FDG uptake was then quantified using the maximum SUV (SUV_max) prior to, and 6 months after the initiation of treatment with anti-TNF-α drugs. Disease activity score (DAS28 and DAS28-C-reactive protein [CRP]) were recorded and white blood cell, matrix metalloproteinases (MMP-3) and rheumatoid factor (RF) were examined in all patients. The average of SUV_max among measured joints, or the sum of these joints (total SUV_max), correlated with DAS28 (r = 0.671, P < 0.001), DAS28-CRP (r = 0.623, P < 0.001), ESR (r = 0.542, P < 0.001), CRP (r = 0.411, P = 0.002), MMP-3 (r = 0.399, P = 0.006), and RF (r = 0.447, P = 0.002). There were correlations between ΔSUV and ΔDAS28 (r = 0.651, P < 0.001), ΔSUV and ΔDAS28-CRP (r = 0.682, P < 0.001), ΔSUV and ΔESR (r = 0.449, P = 0.023), and ΔSUV and ΔMMP-3 (r = 0.457, P = 0.027), respectively. The number of PET-positive joints and the cumulative SUV significantly correlated with the DAS₂₈, which is a composite disease activity score (DAS) that combines the swollen and tender joint counts, the erythrocyte sedimentation rate (DAS₂₈-ESR) or CRP serum levels (DAS₂₈ − CRP) or RF (DAS₂₈ − RF) or metalloproteinases-3 (DAS_28-MMP-3). At baseline and at 6 months' post-treatment with anti-TNFα drugs, there was a significant correlation between the PET results, either visual, the cumulative SUVs or the composite SUV index, and the comprehensive clinical assessment (DAS₂₈), the CRP levels and the number of joints positive for RA, and cumulative synovial thickness. By reflecting inflammatory activity, ¹⁸F-FDG PET may enhance the diagnostic performance and expectation of disease prognosis in RA, especially with early synovial inflammation. The intensity of uptake varied from mild to intense (SUV_max values from 3.10 to 6.0). Overall, these values correlated well with the clinical evaluation of involved joints. ¹⁸F–FDG PET imaging data provided a distribution of joint involvement with varying degrees of severity and phase of disease activity (moderate, low, and remission) in the same patient. PET/CT imaging with ¹⁸F-FDG shows better image quality, provides more confirmative diagnostic information, and will be promising imaging modality in diagnosis and management of RA.

Keywords

Antitumor necrosis factor-α therapy - f-18 fluorodeoxyglucose - positron emission tomography/computed tomography - rheumatoid arthritis - standardized uptake value

Financial support and sponsorship

Nil.

Publikationsverlauf

Eingereicht: 05. März 2020

Angenommen: 18. März 2020

Artikel online veröffentlicht:
19. April 2022

• References

• 1 Almuhaideb A, Papathanasiou N, Bomanji J. ¹⁸F-FDG PET/CT imaging in oncology. Ann Saudi Med 2011;31:3-13.
• 2 Caldarella C, Isgrò MA, Treglia I, Treglia G. Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma? Int J Hematol 2012;96:685-91.
• 3 Palestro CJ. FDG-PET in musculoskeletal infections. Semin Nucl Med 2013;43:367-76.
• 4 Fischer DR. Musculoskeletal imaging using fluoride PET. Semin Nucl Med 2013;43:427-33.
• 5 Carey K, Saboury B, Basu S, Brothers A, Ogdie A, Werner T, et al. Evolving role of FDG PET imaging in assessing joint disorders: A systematic review. Eur J Nucl Med Mol Imaging 2011;38:1939-55.
• 6 Beckers C, Ribbens C, André B, Marcelis S, Kaye O, Mathy L, et al. Assessment of disease activity in rheumatoid arthritis with (18) F-FDG PET. J Nucl Med 2004;45:956-64.
• 7 Kumar NS, Shejul Y, Asopa R, Basu S. Quantitative Metabolic Volumetric Product on 18Fluorine-2fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in assessing treatment response to disease-modifying antirheumatic drugs in rheumatoid arthritis: Multiparametric Analysis Integrating American College of Rheumatology/European League Against Rheumatism Criteria. World J Nucl Med 2017;16:293-302.
• 8 Bhattarai A, Nakajima T, Sapkota S, Arisaka Y, Tokue A, Yonemoto Y, et al. Diagnostic value of 18F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis. Medicine (Baltimore) 2017;96:e7130.
• 9 Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006;31:386-90.
• 10 Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med 2009;23:783-91.
• 11 Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Möttönen T, et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003;48:3077-84.
• 12 Zeman MN, Scott PJ. Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging 2012;2:174-220.
• 13 van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CF, van der Heijden JW, Maruyama K, et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-®-PK11195 and positron emission tomography. Arthritis Rheum 2008;58:3350-5.
• 14 Narváez JA, Narváez J, De Lama E, De Albert M. MR imaging of early rheumatoid arthritis. Radiographics 2010;30:143-63.
• 15 Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol Suppl 2002;66:3-8.
• 16 Hodgson RJ, Connolly S, Barnes T, Eyes B, Campbell RS, Moots R. Pharmacokinetic modeling of dynamic contrast-enhanced MRI of the hand and wrist in rheumatoid arthritis and the response to anti-tumor necrosis factor-alpha therapy. Magn Reson Med 2007;58:482-9.
• 17 Elzinga EH, van der Laken CJ, Comans EF, Lammertsma AA, Dijkmans BA, Voskuyl AE. 2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: Rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 2007;9:357-60.
• 18 Miese F, Scherer A, Ostendorf B, Heinzel A, Lanzman RS, Kröpil P, et al. Hybrid ¹⁸F-FDG PET-MRI of the hand in rheumatoid arthritis: Initial results. Clin Rheumatol 2011;30:1247-50.